1. Adinegoro A, Siregar S, Hardiansyah D, Glatting G. Machine Learning- Data-Driven Time-Integrated Activity Estimation for [ 177 Lu]Lu-PSMA-I&T Therapy in Prostate Cancer. Eur J Nucl Med Mol Imaging 2024; 51
  2. Budiansah I, Hardiansyah D, Pawiro SA, Peters SMB, Konijnenberg MW, Glatting G. Population-Based Model Selection with Nonlinear Mixed-Effects Model (PBMS-NLME) for Renal Dosimetry in [ 177 Lu]Lu-PSMA-617 Therapy using Inter-Occasional and Inter-Individual Variability. Eur J Nucl Med Mol Imaging 2024; 51
  3. Costa G, Orlov C, Yousefzzadeh-Nowshahr E, Fitzpatrick K, Frey K, Beer A, Dewaraja Y, Glatting G. 68Ga-PSMA Receptor Saturation During Radioligand Therapy: Assessment Using a PBPK Model. J Nucl Med 2024; 65.
  4. Costa G, Orlov C, Yousefzzadeh-Nowshahr E, Vasic V, Beer A, Glatting G. Are PBPK Models Enough to Scale Between Mice and Humans? J Nucl Med 2024; 65
  5. Costa G, Yousefzadeh-Nowshahr E, Orlov C, Fitzpatrick K, Frey K, Beer A, Dewaraja Y, Glatting G. Investigation of [ 177 Lu]Lu-PSMA-617 therapy minimum cycle interval with [ 68 Ga]Ga-PSMA-11 PET/CT. Eur J Nucl Med Mol Imaging 2024; 51
  6. Deininger K, Korf P, Lauber L, Grimm R, Strecker R, Steinacker J, Lisson CS, Mühling BM, Schmidtke-Schrezenmeier G, Rasche V, Speidel T, Glatting G, Beer M, Beer AJ, Thaiss W. From Phantoms to Patients: Improved Fusion and Voxel-Wise Analysis of Diffusion-Weighted Imaging and FDG-Positron Emission Tomography in Positron Emission Tomography/Magnetic Resonance Imaging for Combined Metabolic–Diffusivity Index (cDMI). Diagnostics 2024; 14: 1787.
  7. Gaidzik VI, Mayer-Steinacker R, Wittau M, Schultheiß M, A VB, Oehl-Huber K, Dahlum S, Fischer A, Gerstenmaier U, Seufferlein T, Buck A, Beer A, Thaiss W, Möller P, Döhner H, Siebert R, Marienfeld R, Barth TFE. Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients. Sarcoma 2024; 2024: 5036102.
  8. Grunert M, Schenke SA, Konrad A, Schütze C, Förster S, Klemenz B, Stahl AR. Thyroid scintigraphy: establishing a clinically useful normal range for 99mTc pertechnetate uptake. Nuklearmedizin 2024; 63(06): 337-346.
  9. Hardiansyah D, Riana A, Eiber M, Beer AJ, Glatting G. Population-based model selection for an accurate estimation of time-integrated activity using a non-linear mixed-effects modelling. Z Med Phys 2024; 34(3): 419-427.
  10. Hardiansyah D, Riana A, Hänscheid H, Lassmann M, Glatting G. Time-Integrated Activity Calculation for Benign Thyroid Disease using Single-Time-Point Data and Non-Linear Mixed-Effects Modelling. Eur J Nucl Med Mol Imaging 2024; 51
  11. Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F, Beer A, Ruf J, Glatting G, Mix M. Tumor lesion dosimetry of [177Lu]Lu-PSMA-617 therapy using single-time-point data, non-linear mixed-effects modeling and population-based model selection. J Nucl Med 2024; 65.
  12. Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F, Beer A, Ruf J, Glatting G, Mix M. Single-time-point renal dosimetry using non-linear mixed-effects modelling and population-based model selection in [177Lu]Lu-PSMA-617 Therapy. J Nucl Med. 2024; 65(4): 566-572.
  13. Hardiansyah D, Yousefzadeh-Nowshahr E, Kind F, Beer AJ, Ruf J, Mix M, Glatting G. Single-time-point dosimetry for tumour lesions during [ 177 Lu]Lu-PSMA-617 therapy using non-linear mixed-effects modeling. Eur J Nucl Med Mol Imaging 2024; 51.
  14. Harms M, Haase A, Rodríguez-Alfonso A, Löffler J, Almeida-Hernández Y, Ruiz-Blanco YB, Albers D, Gilg A, von Bank F, Zech F, Groß R, Datta M, Jaikishan J, Draphoen B, Habib M, Ständker L, Wiese S, Lindén M, Winter G, Rasche V, Beer AJ, Jumaa H, Abadi AH, Kirchhoff F, Busch M, Dünker N, Sanchez-Garcia E, Münch J. Fatty acid conjugated EPI-X4 derivatives with increased activity and in vivo stability. J Control Release 2024; 373: 583-98.
  15. Hilbrig C, Sievert W, Solbach C, Baumann B, Huber-Lang M, Beer AJ, Rasche V, Loeffler J. Detection of inflammation-related blood-brain barrier disorders using PET and MRI imaging - a pilot study. Eur J Nucl Med Mol Imaging 2024; 51.
  16. Hilbrig C, Winter G, Sievert W, Solbach C, Naumann B, Huber-Lang M, Beer A, Rasche V, Loeffler J. Examining inflammation-induced blood-brain barrier dysfunction: A preclinical study using PET and MR imaging. J Nucl Med 2024; 65: 241694
  17. Ivashchenko O, O’Doherty J, Hardiansyah D, Grassi E, Tran-Gia J, Heemskerk JWT, Hippelainen E, Sandström M, Cremonesi M, Glatting G. Understanding Time-Activity Curve and Time-Integrated Activity Variations in Radiopharmaceutical Therapy: Experience from the TACTIC AAPM Grand Challenge 2023. Eur J Nucl Med Mol Imaging 2024; 51.
  18. Ivashchenko OV, O'Doherty J, Hardiansyah D, Cremonesi M, Tran-Gia J, Hippeläinen E, Stokke C, Grassi E, Sandström M, Glatting G. Time-Activity data fitting in molecular Radiotherapy: Methodology and pitfalls. Phys Med 2024; 117: 103192.
  19. Kiess AP, O'Donoghue J, Uribe C, Bodei L, Hobbs RF, Hesterman J, et al. How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design. J Clin Oncol. 2024; 12(7): 1460.
  20. Lugnier C, Sommerlatte S, Attenberger U, Beer AJ, Bentz M, Benz SR, Birkner T, Büntzel J, Ebert MPA, Fasching P, Fischbach W, Fokas E, Fricke B, Hense H, Grohmann E, Hofheinz RD, Hüppe D, Huster S, Jahn P, Klinkhammer-Schalke M, Knauf W, Kraeft AL, Maier BO, Marckmann G, Niegisch G, Otto L, Pelzer U, Piso P, Rosenau H, Schmitt J, Schoffer O, Sehouli J, Tannapfel A, Wedding U, Wesselmann S, Winkler EC, Zimmermann T, Wörmann B, Reinacher-Schick A, Schildmann J. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Oncol Res Treat 2024; 47: 296-305.
  21. Orlov C, Yousefzadeh-Nowshahr E, Begum NJ, Vasic V, Beer AJ, Glatting G, Eiber M. Streamlining Parameter Dimensionality in a PBPK Model for [ 177 Lu]Lu-PSMA I&T Radioligand Therapy using Bayesian Parameter Estimation. Eur J Nucl Med Mol Imaging 2024; 51
  22. Prasad V, Kneer H, Kull T, Zengerling F, Miksch J, Beer A. Is it feasible to perform radiopharmaceutical therapies in patients with dialyses: Experience from a comprehensive cancer center in Germany. J Nucl Med 2024; 65.
  23. Prex V, Gilg A, Rasche V, Münch J, Beer A, Harms M, Löffler J. Utilizing the chicken chorioallantoic membrane model to assess CXCR4 targeting agents for cancer therapy using multimodal imaging. Eur J Nucl Med Mol Imaging 2024; 51.
  24. Seeling C, Dahlum S, Marienfeld R, Hallebach V, Rack B, Gerstenmaier U, Beer A, Mayer-Steinacker R, Thaiss WM, Barth T, Seufferlein T, Gaisa NT, Stilgenbauer S, Janni W, Doehner H, Siebert R, Gaidzik V ;Exploiting somatic oncogenic driver alterations in a patient with Li-Fraumeni-Syndrome - Paving the path towards precision medicine. Oncol Res Treat 2024; 47: 223.
  25. Sollmann N, Hoffmann G, Schramm S, Reichert M, Hernandez Petzsche M, Strobel J, Nigris L, Kloth C, Rosskopf J, Börner C, Bonfert M, Berndt M, Grön G, Müller HP, Kassubek J, Kreiser K, Koerte IK, Liebl H, Beer A, Zimmer C, Beer M, Kaczmarz S. Arterial Spin Labeling (ASL) in Neuroradiological Diagnostics - Methodological Overview and Use Cases. Röfo 2024; 196(1): 36-51.
  26. Steube D, Hillenhagen H, Stilgenbauer S, Beer AJ, Beer M, Götz M, Thaiss W, Glatting G. Deep learning-based classification and segmentation of whole-body  18 F-FDG PET/CT examinations using manually generated segmentation masks. Eur J Nucl Med Mol Imaging 2024; 51
  27. Strauß AS, Bolenz C, Beer AJ, Zengerling F, Beer M, Miksch J. [Erratum to: Opportunities for prostate-specific membrane antigen hybrid imaging in prostate cancer]. Urologie 2024; 63: 102.
  28. Strobel J, Yousefzadeh-Nowshahr E, Deininger K, Bohn KP, von Arnim CAF, Otto M, Solbach C, Anderl-Straub S, Polivka D, Fissler P, Glatting G, Riepe MW, Higuchi M, Beer AJ, Ludolph A, Winter G. Exploratory Tau PET/CT with [11C]PBB3 in Patients with Suspected Alzheimer’s Disease and Frontotemporal Lobar Degeneration: A Pilot Study on Correlation with PET Imaging and Cerebrospinal Fluid Biomarkers. Biomedicines 2024; 12: 1460.
  29. Ursprung S, Thaiss W, Beha J, Möller Y, Malek NP, Beer M, Gaidzik VI, Seufferlein T, Beer AJ, Nikolaou K, Reinert CP. Standardized Response Assessment in Patients with Advanced Cholangiocarcinoma Treated with Personalized Therapy. J Pers Med 2024; 14(12):1143.
  30. Vasić V, Gustafsson J, Nowshahr EY, Stenvall A, Beer AJ, Gleisner KS, Glatting G. A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology. Phys Med 2024; 119: 103299
  31. Vasic V, Gustafsson J, Yousefzadeh-Nowshahr E, Beer A, Sjogreen Gleisner K, Glatting G. Treatment Planning in Neuroendocrine Tumors: Utilizing a Single Individual Time-Point [68Ga]Ga-DOTA-TATE PET/CT Measurement for [177Lu]Lu-DOTA-TATE Therapy. J Nucl Med 2024; 65.
  32. Wicaksono A, Siregar S, Jabar J, Hardiansyah D, Glatting G. Time-Integrated Activity Estimation of [ 177 Lu]Lu-PSMA-617 Using Single-Time-Point Data and a Machine Learning Models. Eur J Nucl Med Mol Imaging 2024; 51